EUVIMEDEUVIMED entdecken
Fallbericht

Placental and breast milk transfer of belimumab in three patients with systemic lupus erythematosus treated throughout pregnancy

Akitsu Higuchi iD, Jumpei Saito iD, Kentaro Fujimori, Takashi Ishikawa iD, Hiroyo Kawasaki, Eiko Miyagawa, Sawako Abe, Chie Kohno, Chinatsu Takai, Yuka Sano Wada iD, Toshinao Kawai, Atsuko Murashima iD und 1 weitere

Modern Rheumatology Case Reports · 2025

DOI: 10.1093/mrcr/rxaf038 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2025. Verfasst von Akitsu Higuchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Maternal Medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, Humanized, Milk, Human, Pregnancy Complications. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: AMED, Health and Labour Sciences Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The safety of belimumab during pregnancy, particularly in the third trimester, remains unclear. This study aimed to assess the placental and breast milk transfer of belimumab in pregnancies complicated by systemic lupus erythematosus and to evaluate immunological effects and vaccination responses in offspring. We prospectively followed three patients with systemic lupus erythematosus who received belimumab throughout pregnancy. Belimumab concentrations were measured in maternal serum, cord blood, breast milk, and neonatal serum, along with infant development and vaccination histories. Belimumab was continued throughout pregnancy to control refractory thrombocytopenia in two cases and haemolytic anaemia in one case. All patients delivered full-term infants without obstetric complications. Overall, belimumab concentrations in cord blood and neonatal serum were comparable to those in the maternal serum, suggesting transplacental transfer. A decrease in peripheral B and transitional B cells was observed in all neonates at birth, while serum IgG levels and peripheral T cell counts were within normal ranges. Only one infant was diagnosed with a complication (left vesicoureteral reflux). Belimumab concentrations in breast milk were low, and no adverse events occurred in the vaccinated infants. Continuation of belimumab throughout pregnancy may be an option to control refractory disease activity and achieve successful outcomes in pregnancies complicated by systemic lupus erythematosus. However, careful monitoring during pregnancy and postnatal follow-up is essential to ensure safety, given that belimumab can be transferred to the placenta, detected in the neonatal peripheral blood, and affect the neonatal lymphocyte subset counts at birth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAntibodies, Monoclonal, HumanizedMilk, HumanPregnancy ComplicationsImmunosuppressive AgentsPlacentaMaternal-Fetal ExchangeHumansFemalePregnancyAdultInfant, NewbornFetal Blood

Stichwörter der Autor:innen

Systemic lupus erythematosusbelimumabbreastfeedingplacental transferpregnancy

Substanzen

Antibodies, Monoclonal, HumanizedbelimumabImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Maternal Medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Pharmacy, National Center for Child Health and Development, Tokyo, Japan.
  • Division of Immunology, National Center for Child Health and Development, Tokyo, Japan.
  • Division of Neonatology, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.
  • Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.

ORCID-Profile: Akitsu Higuchi, Jumpei Saito, Takashi Ishikawa, Yuka Sano Wada, Atsuko Murashima, Kayoko Kaneko

Förderung

  • AMED
  • Health and Labour Sciences Research

Zitieren

APA

Higuchi, A., Saito, J., Fujimori, K., Ishikawa, T., Kawasaki, H., Miyagawa, E., Abe, S., Kohno, C., Takai, C., Wada, Y. S., Kawai, T., Murashima, A., & Kaneko, K. (2025). Placental and breast milk transfer of belimumab in three patients with systemic lupus erythematosus treated throughout pregnancy. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxaf038

Vancouver

Higuchi A, Saito J, Fujimori K, Ishikawa T, Kawasaki H, Miyagawa E, et al. Placental and breast milk transfer of belimumab in three patients with systemic lupus erythematosus treated throughout pregnancy. Modern Rheumatology Case Reports. 2025. doi:10.1093/mrcr/rxaf038

BibTeX
@article{Higuchi2025,
  author = {Higuchi, Akitsu and Saito, Jumpei and Fujimori, Kentaro and Ishikawa, Takashi and Kawasaki, Hiroyo and Miyagawa, Eiko and Abe, Sawako and Kohno, Chie and Takai, Chinatsu and Wada, Yuka Sano and Kawai, Toshinao and Murashima, Atsuko and Kaneko, Kayoko},
  title = {Placental and breast milk transfer of belimumab in three patients with systemic lupus erythematosus treated throughout pregnancy},
  journal = {Modern Rheumatology Case Reports},
  year = {2025},
  doi = {10.1093/mrcr/rxaf038}
}
Kostenlos starten →